Carcinogenesis, Vol. 24, No. 3, 605-611,
March 2003
© 2003 Oxford University Press
CARCINOGENESIS |
Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations
1 Strang Cancer Research Laboratory at The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA,
2 American Health Foundation, Valhalla, NY 10595, USA,
3 Albert Einstein College of Medicine, Bronx, NY 10461, USA,
4 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA and
5 Division of Genetics, Brigham and Women Hospital, Boston, MA 02115, USA
Sulindac and other NSAIDs have been widely studied as potential chemopreventive agents for colon cancer. Short-term studies have shown adenomatous polyps to regress in patients with familial adenomatous polyposis (FAP). In this study the effect of sulindac on cancer as an endpoint was evaluated in ApcMin mice, a preclinical model of FAP with an Apc mutation in codon 850 that leads to gastrointestinal adenomas and carcinomas. Three groups of mice were studied all of which were fed AIN-76A diet: one group was fed AIN-76A diet alone, a second group received sulindac 200 p.p.m. premixed in the diet and a third group received sulindac 180 p.p.m. added in drinking water. ApcMin mice were killed 9 weeks after feeding was initiated. Mice receiving sulindac developed fewer tumors in the intestine overall; the major decrease in tumor development after sulindac was seen in the small intestine regardless of route of administration. In the large intestine, however, sulindac significantly increased the incidence, multiplicity and volume of tumors in the colon of ApcMin mice, a regional response to sulindac differing from previous reports. Quantitative measurements of apoptosis, Bax and Bcl-xL protein expression in the ApcMin mice revealed the ratio of Bax/Bcl-xL expression and apoptosis increased in the small intestine but decreased in the cecum, consistent with the regional tumorigenesis observed after sulindac. These findings thus suggest involvement of Bax and apoptosis in tumors developing after sulindac treatment in this mouse model.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Yang, S. A. Lamprecht, H. Shinozaki, K. Fan, W. Yang, H. L. Newmark, L. Kopelovich, W. Edelmann, B. Jin, C. Gravaghi, et al. Dietary Calcium and Cholecalciferol Modulate Cyclin D1 Expression, Apoptosis, and Tumorigenesis in Intestine of adenomatous polyposis coli1638N/+ Mice J. Nutr., September 1, 2008; 138(9): 1658 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Baltgalvis, F. G. Berger, M. M. O. Pena, J. M. Davis, and J. A. Carson Effect of exercise on biological pathways in ApcMin/+ mouse intestinal polyps J Appl Physiol, April 1, 2008; 104(4): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Misikangas, A.-M. Pajari, E. Paivarinta, S. I. Oikarinen, J. Rajakangas, M. Marttinen, H. Tanayama, R. Torronen, and M. Mutanen Three Nordic Berries Inhibit Intestinal Tumorigenesis in Multiple Intestinal Neoplasia/+ Mice by Modulating {beta}-Catenin Signaling in the Tumor and Transcription in the Mucosa J. Nutr., October 1, 2007; 137(10): 2285 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Chao and S. M. Lipkin Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis Nucleic Acids Res., February 6, 2006; 34(3): 840 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oida, B. Gopalan, R. Miyahara, S. Inoue, C. D. Branch, A. M. Mhashilkar, E. Lin, B. N. Bekele, J. A. Roth, S. Chada, et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer Mol. Cancer Ther., February 1, 2005; 4(2): 291 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Khwaja, J. Allen, J. Lynch, P. Andrews, and D. Djakiew Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75NTR Tumor Suppressor Protein Cancer Res., September 1, 2004; 64(17): 6207 - 6213. [Abstract] [Full Text] [PDF]
|
|